The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of \[14C\]PF-04991532 in healthy adult male subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
6
a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
Pfizer Investigational Site
Tacoma, Washington, United States
Mass Balance: Urinary and fecal excretion of radioactivity over time expressed as a percentage of the total radioactive dose administered.
Time frame: 0-168 hrs
Metabolic Profiling/identification and determination of relative abundance of PF-04991532 and the metabolites of PF-04991532 in plasma, urine, and feces.
Time frame: 0-168 hrs
radioactivity AUC
Time frame: 0-168 hrs
plasma PF-04991532 AUC
Time frame: 0-168 hrs
radioactivity Cmax
Time frame: 0-168 hrs
plasma PF-04991532 Cmax
Time frame: 0-168 hrs
plasma PF-04991532 Tmax
Time frame: 0-168 hrs
radioactivity Tmax
Time frame: 0-168 hrs
plasma PF-04991532 t1/2
Time frame: 0-168 hrs
radioactivity t1/2
Time frame: 0-168 hrs
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.